Pruritus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
Dallas, Texas (PRWEB) April 07, 2015 -- The report “Pruritus - Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Pruritus. Pruritus is a common symptom, rather than a specific disease entity, that occurs in a diverse range of skin diseases and may appear as a prominent feature of extracutaneous disorders such as systemic, neurologic, and psychiatric diseases. The incidence of pruritus increases with age and is one of the most common complaints in the elderly patient population. Most often dry skin, otherwise known as xerosis is the commonest cause in these patients. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/pruritus-pipeline-review-h1-2015-market-report.html .
The report also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. Companies discussed in this Pruritus – Pipeline Review, H1 2015 report include AlbireoPharma, Amorepacific Corporation, Cara Therapeutics, Inc., Conrig Pharma ApS, Creabilis SA, ELORAC, Inc., FAES Farma SA, GlaxoSmithKline plc, Helsinn Holding S.A., Hydra Biosciences, Inc., LEO Pharma A/S, Merck & Co., Inc., NeRRe Therapeutics Ltd, Nippon Shinyaku Co., Ltd., RDD Pharma Ltd., Shionogi & Co., Ltd., Tioga Pharmaceuticals, Inc., Trevi Therapeutics, Inc. and Vanda Pharmaceuticals Inc.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Drug Profiles mentioned in this report are A-4250, aprepitant, asimadoline, ASN-008, bilastine, C-746, CR-845, CRG-010, CT-327, desloratadine, Drugs to Target Mas-Related G-Protein Coupled Receptor for Pruritus, GSK-2330672, nalbuphine hydrochloride ER, naloxone hydrochloride, netupitant, NS-141, orvepitant maleate, PAC-14028, PP-120, serlopitant, Small Molecule for Pruritus Ani, Small Molecule to Agonize CB2 for Pruritus, Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis, Small Molecules to Block NaV1.7 Channel for Pain and Pruritus and tradipitant. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=347018 . (This is a premium report priced at US$2000 for a single user License.)
List of Tables
Number of Products under Development for Pruritus, H1 2015 9
Number of Products under Development for Pruritus - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Pruritus - Pipeline by AlbireoPharma, H1 2015 20
Pruritus - Pipeline by Amorepacific Corporation, H1 2015 21
Pruritus - Pipeline by Cara Therapeutics, Inc., H1 2015 22
Pruritus - Pipeline by Conrig Pharma ApS, H1 2015 23
Pruritus - Pipeline by Creabilis SA, H1 2015 24
Pruritus - Pipeline by ELORAC, Inc., H1 2015 25
Pruritus - Pipeline by FAES Farma SA, H1 2015 26
Pruritus - Pipeline by GlaxoSmithKline plc, H1 2015 27
Pruritus - Pipeline by Helsinn Holding S.A., H1 2015 28
Pruritus - Pipeline by Hydra Biosciences, Inc., H1 2015 29
Pruritus - Pipeline by LEO Pharma A/S, H1 2015 30
Pruritus - Pipeline by Merck & Co., Inc., H1 2015 31
Pruritus - Pipeline by NeRRe Therapeutics Ltd, H1 2015 32
Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 33
Pruritus - Pipeline by RDD Pharma Ltd., H1 2015 34
Pruritus - Pipeline by Shionogi & Co., Ltd., H1 2015 35
Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H1 2015 36
Pruritus - Pipeline by Trevi Therapeutics, Inc., H1 2015 37
Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 43
Number of Products by Stage and Route of Administration, H1 2015 45
Number of Products by Stage and Molecule Type, H1 2015 47
Pruritus Therapeutics - Recent Pipeline Updates, H1 2015 79
Pruritus - Dormant Projects, H1 2015 88
Pruritus - Discontinued Products, H1 2015 89
List of Figures
Number of Products under Development for Pruritus, H1 2015 9
Number of Products under Development for Pruritus - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Products, H1 2015 16
Explore more reports on Dermatology therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article